SpIDnet project

Invasive pneumococcal disease in European Union and European Economic Area

Streptococcus pneumoniae constitutes a major public health problem worldwide. Invasive pneumococcal disease (IPD), defined according to EU 2012 case definition as the isolation or detection of S. pneumoniae through PCR or antigen testing in a normally sterile fluid, may present as different syndromes, from mild bacteraemia to septic shock. IPD has thus no clinical definition, but is only based on testing of sterile fluids such as blood, cerebrospinal fluid, pleural fluid etc. This implies that reported IPD rates vary across countries, depending on clinical practices (such as recourse to blood testing), organisation of health care and surveillance systems.

Based on capsule polysaccharide composition, almost 100 serotypes have been so far identified. The epidemiology of these serotypes is complex: their incidence differs by area and age group and may vary over time, following cyclical and unpredictable patterns; these serotypes also differ in pathogenicity and case fatality.

Two major groups of pneumococcal vaccines are currently available: polysaccharide vaccines, i.e. 23-valent vaccine (PPV23) and more recently conjugate vaccines (PCV). The currently available PCV vaccines covering 10 and 13 serotypes have gradually replaced the 7-valent vaccine in most European countries starting 2009.


The scope of the project is to maintain and further develop the enhanced, population‐based IPD surveillance system in order to sustain IPD surveillance and vaccination impact assessment in the EU/EEA.

The objectives of the project as stated in the tender specifications are:
  • To maintain and further develop a coordination infrastructure and a network of reporting sites for enhanced, population‐based IPD surveillance in the EU/EEA;
  • To estimate the incidence rate and mortality due to IPD in children and adults;
  • To provide systematic monitoring of circulating S. pneumoniae serotypes in order to detect emerging strains and serotype replacement;
  • To measure the vaccine effectiveness of the pneumococcal conjugate vaccines
  • To evaluate the impact of pneumococcal conjugate vaccines in terms of the disease burden of vaccine and non‐vaccine strains;
  • To monitor antimicrobial non‐susceptibility in pneumococcal isolates.

Project history

SpIDnet (Streptococcus pneumoniae Invasive Disease network) was set up in 2012 in response to the European Centre for Disease Prevention and Control (ECDC) call for tender on “Assessing the impact of vaccination with conjugate vaccines on the epidemiology of invasive pneumococcal disease in Europe” (ECDC/2012/038). Twelve partners institutions from nine EU member states coordinated by EpiConcept participated in the first phase of the project 2012-2014.

In 2014, the project added adult component according to Service Contract - ECD.5107 implementing complementary activities to the Framework Contract ECDC/2012/038 “Assessing the impact of vaccination with conjugate vaccines on the epidemiology of the invasive pneumococcal disease in Europe”.

In 2015, the project extended to 15 partners from 10 EU member states - SpIDnet2 project: “Assessing the impact of vaccination with conjugate vaccines on the epidemiology of invasive pneumococcal disease in Europe” (ECDC/2015/031).

Access to Members Area

Request protocols or contact us at: spidnet@epiconcept.fr

Sous-pages (2) : References The network